Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × zimberelimab × 90 days × Clear all

Phase

Phase 2 12 Phase 1 6 Phase 3 2 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 86 Carboplatin 51 Cyclophosphamide 49 Nivolumab 42 Specimen Handling 38 fludarabine 36 Magnetic Resonance Spectroscopy 36 Gemcitabine 35 Biopsy 34 Dexamethasone 33 Bevacizumab 33 Paclitaxel 30 venetoclax 27 Cisplatin 27 atezolizumab 26 Temozolomide 24 Injections 23 Rituximab 20 Pemetrexed 20 Irinotecan 20 Docetaxel 18 Cetuximab 17 Fluorouracil 16 Azacitidine 16 durvalumab 15 Radiotherapy 15 Prednisone 15 Oxaliplatin 15 Lenalidomide 15 abemaciclib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡